Thompson Davis & Co’s CorMedix CRMD Stock Holding History

Thompson Davis & Co’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-400	Closed	–	–	722
2018 Q2	$0	Hold	400	–	–	﹤0.01%	679
2018 Q1	$0	Hold	400	–	–	﹤0.01%	644
2017 Q4	$1K	Hold	400	–	–	﹤0.01%	632
2017 Q3	$1K	Buy	+400	New	+$829	﹤0.01%	1063

Other funds holding CRMD

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Planning Directions Glen Mills, Pennsylvania $216M AUM 18.03% 1-Year Est. Return

Thompson Davis & Co's CRMD Position: Q3 2018 in Review

Thompson Davis & Co sold out of CorMedix (CRMD) in Q3 2018, closing a stake of 400 shares.

Thompson Davis & Co first reported a position in CRMD in Q3 2017 and held it in 4 quarters. The position peaked at $1K in Q4 2017. 33 funds tracked by Wall St. Rank hold CRMD as of Q3 2018.

Thompson Davis & Co reported no remaining CorMedix position as of Q3 2018 after selling out during the quarter.
Thompson Davis & Co sold 400 CorMedix shares in Q3 2018.
Thompson Davis & Co first reported a position in CorMedix in Q3 2017 and held it in 4 quarters.
Thompson Davis & Co's CorMedix position peaked at $1K in Q4 2017.
33 funds tracked by Wall St. Rank held CorMedix as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.